The CRISPR patent portfolio licensed via ERS (known as the CVC portfolio) is the most comprehensive collection of proprietary rights to the fundamental CRISPR/Cas9 gene editing platform.
Built on the Nobel Prize winning work of Emmanuelle Charpentier and Jennifer Doudna, ERS grants non-exclusive licenses to a growing list of issued and pending patent applications globally, in all fields excluding direct use as a human therapeutic.
Where in the world are our patents issued
50 issued patents
7 issued patents
International (including China and Japan)
37 issued patents
What do the CVC Patents cover?
The CVC inventors have been awarded three broad patents on the CRISPR/Cas9 technology that include claims to the following:
- A composition comprising a chimeric Cas9 protein and a DNA targeting RNA which includes a DNA-targeting segment and a protein-binding segment comprising tracrRNA and CRISPR RNA (crRNA)
- A method of modifying a target DNA in a single-cell eukaryotic organism, an animal cell, or a plant cell comprising contacting the target DNA with a CRISPR/Cas9 complex
- A method of modifying a target DNA comprising contacting the target DNA with a CRISPR/Cas9 complex where the crRNA and tracrRNA are covalently linked by intervening nucleotides (single guide RNA)
In the USA
The CVC portfolio contains issued, allowed and pending patents which include claims to the following:
- Compositions and methods of using Cas9 with a guide RNA to form a CRISPR/Cas9 complex that binds a specified DNA sequence
- Various formats for delivering these complexes in cells of all types
- Use of the CRISPR/Cas9 complex to cleave DNA (resulting in knock-outs, insertions or mutations)
- Use of mutated Cas9 to ‘nick’ DNA (in place of cleavage) or to bring an effector domain to a specified DNA sequence to regulate gene expression in a cell
- Compositions of guide RNAs in a variety of formats including various lengths, chemical modifications, and base compositions